1. Home
  2. TRMK vs BEAM Comparison

TRMK vs BEAM Comparison

Compare TRMK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trustmark Corporation

TRMK

Trustmark Corporation

N/A

Current Price

$45.11

Market Cap

2.6B

Sector

Finance

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.50

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRMK
BEAM
Founded
1889
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.8B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
TRMK
BEAM
Price
$45.11
$26.50
Analyst Decision
Hold
Strong Buy
Analyst Count
6
15
Target Price
★ $49.80
$49.38
AVG Volume (30 Days)
389.8K
★ 1.8M
Earning Date
10-27-2026
11-03-2026
Dividend Yield
★ 2.22%
N/A
EPS Growth
1.93
★ 82.31
EPS
★ 2.03
N/A
Revenue
N/A
★ $24,000.00
Revenue This Year
$2.80
N/A
Revenue Next Year
$8.08
$39.57
P/E Ratio
$22.12
★ N/A
Revenue Growth
N/A
★ 33.33
52 Week Low
$36.41
$20.23
52 Week High
$49.00
$38.26

Technical Indicators

Market Signals
Indicator
TRMK
BEAM
Relative Strength Index (RSI) 49.12 55.45
Support Level $45.03 $25.29
Resistance Level $45.60 $28.87
Average True Range (ATR) 0.97 1.56
MACD 0.02 0.33
Stochastic Oscillator 43.30 56.51

Price Performance

Historical Comparison
TRMK
BEAM

About TRMK Trustmark Corporation

Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: